Design of novel nanomedicine containing NSAIDs for improvement of drug-induced gastrointestinal lesions
| Project/Area Number |
15K08115
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ナノ結晶製剤 / 口腔内崩壊錠 / NSAIDs / 消化管傷害 / 関節リウマチ / バイオアベイラビリティ / ビーズミル / 湿式破砕 |
|---|
| Outline of Final Research Achievements |
We designed new oral formulations containing nonsteroidal anti-inflammatory drugs (NSAIDs), such as meloxicam (MLX) solid nanoparticles, and investigate their usefulness by evaluating bioavailability and gastrointestinal lesions. The MLX solid nanoparticles were prepared using a bead mill method, and high quality dispersions containing MLX nanoparticles were prepared (MLXnano, particle size: 48 ± 138 nm, means± S.D.). The bioavailability in MLXnano was 4.3-fold higher in comparison with that in conventional MLX, and the MLX-induced gastrointestinal lesions in rats administered MLXnano, in consideration of bioavailability, were significantly less than for conventional MLX. An oral drug delivery system using drug nanoparticles may expand the usage of NSAIDs for therapy in the inflammatory field.
|
Report
(4 results)
Research Products
(18 results)
